The North Chicago-based biopharmaceutical firm confirmed the decision on Wednesday. For those living with non-segmental vitiligo—a condition characterized by symmetrical white skin patches—this represents a new therapeutic path, as previous options lacked systemic efficacy. The approval also covers severe cases of alopecia areata, an autoimmune disease that triggers unpredictable hair loss.
In section Market Quotes
AbbVie Wins European Approval for Rinvoq in Skin and Hair Disorders
The European Commission has cleared AbbVie’s blockbuster medication Rinvoq to treat patients aged 12 and older suffering from severe alopecia areata and non-segmental vitiligo. This regulatory expansion marks a significant shift, establishing the drug as the first systemic treatment available across Europe for the most common form of pigment loss.
AbbVie continues to leverage the drug’s versatility as a key driver of its financial performance. With existing authorizations for several other autoimmune conditions, the company projects annual revenue from Rinvoq to exceed $10 billion this year, cementing its status as a cornerstone of their portfolio.
Comments (0)
No comments yet. Be the first!